What Pandemic? Joinn Lab Posts Bumper Profit Despite Covid Disruptions
Less affected by Covid-control measures that have clobbered many Chinese businesses, the pre-clinical contract research organization’s profit more than doubled in the first three quarters of 2022.
版權(quán)聲明：本文版權(quán)歸FT中文網(wǎng)所有，未經(jīng)允許任何單位或個(gè)人不得轉(zhuǎn)載，復(fù)制或以任何其他方式使用本文全部或部分，侵權(quán)必究。